Dublin, Aug. 19, 2019 (GLOBE NEWSWIRE) -- The "Orthostatic Hypotension Drugs Market by Product and Geography - Global Forecast and Analysis 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Increasing prevalence of chronic diseases associated with high risk of OH

The prevalence of the neurodegenerative diseases, cardiovascular diseases and diabetes is significantly increasing worldwide, raising the risk of OH. It is associated with an underlying autonomic neurologic disorder. Dehydration is also a common condition in people which increases the risk of OH and causing damage to the nerves.

This increase in prevalence of chronic diseases associated with high risk of OH will lead to the expansion of the global orthostatic hypotension drugs market at a CAGR of almost 8% during the forecast period.

Rise in the use of combination therapy in OH treatment

OH, is a chronic debilitating illness that is difficult to treat in several patients. Single drug therapy might not be adequate in treating OH patients as orthostatic stress varies with circumstances during the day. This has led to the increasing focus on the use of combination therapy in OH treatment. This development is expected to have a positive impact on the overall market growth.

Market Dynamics

Also, our global orthostatic hypotension drugs market report looks at factors such as increasing prevalence of OH in geriatric population, increasing prevalence of chronic diseases associated with high risk of OH, and high market growth opportunities for OH drugs in emerging countries.

However, the uncertainties in low diagnosis rate, lack of clinical evidence and unfavorable safety profile of OH drugs, and adoption of non-pharmacological treatment options as first line therapy may hamper the growth of orthostatic hypotension drugs market over the forecast period.

Segment Analysis

The orthostatic hypotension drugs market analysis considers sale from midodrine, northera (droxidopa), fludrocortisone, and other drugs. Our analysis also considers the orthostatic hypotension drugs market in Asia, Europe, North America, and RoW.

In 2018, the midodrine segment had a significant share. However, the Northera (droxidopa) segment will grow faster and emerge as the market leader by the end of the forecast period. Northera can activate alpha 1 adrenergic receptors and have numerous physiological effects that may ameliorate the symptoms of nOH. This will contribute to the demand for Northera over the forecast period.

Competitive Landscape

With the presence of several major players, global orthostatic hypotension drugs market is moderately fragmented. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several orthostatic hypotension drugs manufacturers, that include:

• Amneal Pharmaceuticals Inc.
• H. Lundbeck AS
• Mylan N.V.
• Novartis AG
• Pfizer Inc.

Also, orthostatic hypotension drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Key Topics Covered

PART 01: Executive Summary

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

• Comparison by product
• Midodrine - Market size and forecast 2018-2023
• Northera (droxidopa) - Market size and forecast 2018-2023
• Fludrocortisone - Market size and forecast 2018-2023
• Other drugs - Market size and forecast 2018-2023
• Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• RoW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

• R&D of new drugs for OH treatment
• Use of combination therapy in OH treatment
• Adoption of fludrocortisone as off-label first-line pharmacotherapy

PART 12: VENDOR LANDSCAPE

• Overview
• Landscape disruption

PART 13: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Amneal Pharmaceuticals Inc.
• H. Lundbeck AS
• Mylan N.V.
• Novartis AG
• Pfizer Inc.

For more information about this report visit https://www.researchandmarkets.com/r/b8fzuw

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900